Co-Diagnostics
CODX
10 hedge funds and large institutions have $1.92M invested in Co-Diagnostics in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
487% more capital invested
Capital invested by funds: $327K → $1.92M (+$1.59M)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
43% more funds holding
Funds holding: 7 → 10 (+3)
9% more ownership
Funds ownership: 1.74% → 10.74% (+9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$928K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$850K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$108K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
+$25.2K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$34K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.71K |
CODX Hedge Fund Activity: Q1 2019 in Review
10 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q1 2019, worth a combined $1.92M — up 487% from $327K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CODX positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $928K. The largest seller was Citadel Advisors, exiting entirely with an estimated $34K sold.
- 10 institutional investors held Co-Diagnostics (CODX) as of Q1 2019, up from 7 in Q4 2018.
- Funds reported $1.92M of Co-Diagnostics stock for Q1 2019, up 487% quarter-over-quarter.
- 5 funds opened new Co-Diagnostics positions in Q1 2019 and 2 closed out, a net change of +3 holders.
- The largest Co-Diagnostics buyer in Q1 2019 was Sabby Management, an estimated $928K added.
- The largest Co-Diagnostics seller in Q1 2019 was Citadel Advisors, an estimated $34K sold.
Based on aggregated 13F filings for Q1 2019.